lopinavir/ritonavir - for COVID-19 mild to moderate   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical worsening 3.69 [0.37, 36.57]< 10%1 study (1/-)13.4 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.43 [0.08, 2.20]> 161%2 studies (2/-)15.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 1.28 [0.19, 8.76]> 10%1 study (1/-)59.9 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 0.30 [0.05, 1.91]> 10%1 study (1/-)10.3 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 0.48 [0.02, 11.28]> 10%1 study (1/-)32.8 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.10 [0.00, 2.09]> 10%1 study (1/-)7.2 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 90 90